Article Text

Download PDFPDF
Randomised controlled trial
Coronary artery bypass graft surgery provides clinically important quality-of-life improvements over medical therapy in patients with ischaemic left ventricular dysfunction
  1. Denis Bouchard
  1. Correspondence to : Dr Denis Bouchard, Department of Surgery, Montreal Heart Institute, 5000 Bélanger est, Montréal, H1T 1C8, Canada; Denis.Bouchard{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science.


Early clinical trials comparing coronary artery bypass graft (CABG) surgery to medical treatments in the 1970s and 1980s indicate an improved survival for surgery patients with left ventricular (LV) dysfunction. However, patients with severe LV dysfunction were not represented in these trials.1 Surgical Treatment for Ischaemic Heart Failure (STICH) was a trial aimed at comparing CABG surgery to the optimal medical therapy in ischaemic cardiomyopathy patients with an ejection fraction (EF) <0.35. A major secondary end point of the trial was health-related quality of life (QOL). These are the outcomes presented in this paper.


Patients (n=1212) with EF of 0.35 or less and coronary artery disease …

View Full Text


  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Commissioned; internally peer reviewed.